218 related articles for article (PubMed ID: 24494707)
1. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases.
Hagiwara M; Delea TE; Chung K
J Med Econ; 2014 Mar; 17(3):223-30. PubMed ID: 24494707
[TBL] [Abstract][Full Text] [Related]
2. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.
Hagiwara M; Delea TE; Saville MW; Chung K
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):23-7. PubMed ID: 23146970
[TBL] [Abstract][Full Text] [Related]
3. The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium.
Body JJ; Chevalier P; Gunther O; Hechmati G; Lamotte M
J Med Econ; 2013; 16(4):539-46. PubMed ID: 23425250
[TBL] [Abstract][Full Text] [Related]
4. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
5. Canadian health care institution resource utilization resulting from skeletal-related events.
Habib MJ; Merali T; Mills A; Uon V
Hosp Pract (1995); 2014 Feb; 42(1):15-22. PubMed ID: 24566592
[TBL] [Abstract][Full Text] [Related]
6. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.
Barlev A; Song X; Ivanov B; Setty V; Chung K
J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255
[TBL] [Abstract][Full Text] [Related]
7. Cost of skeletal complications from bone metastases in six European countries.
Pereira J; Body JJ; Gunther O; Sleeboom H; Hechmati G; Maniadakis N; Terpos E; Acklin YP; Finek J; von Moos R
J Med Econ; 2016 Jun; 19(6):611-8. PubMed ID: 26849381
[TBL] [Abstract][Full Text] [Related]
8. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
[TBL] [Abstract][Full Text] [Related]
11. Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma.
Nash Smyth E; Conti I; Wooldridge JE; Bowman L; Li L; Nelson DR; Ball DE
J Med Econ; 2016; 19(5):477-86. PubMed ID: 26671598
[TBL] [Abstract][Full Text] [Related]
12. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study.
Hechmati G; Cure S; Gouépo A; Hoefeler H; Lorusso V; Lüftner D; Duran I; Garzon-Rodriguez C; Ashcroft J; Wei R; Ghelani P; Bahl A
J Med Econ; 2013; 16(5):691-700. PubMed ID: 23441975
[TBL] [Abstract][Full Text] [Related]
13. Short-term disability in solid tumor patients with bone metastases and skeletal-related events.
Qian Y; Song X; Zhang K; Balakumaran A; Arellano J
J Med Econ; 2015 Mar; 18(3):210-8. PubMed ID: 25426582
[TBL] [Abstract][Full Text] [Related]
14. The cost of treating skeletal-related events in patients with prostate cancer.
Lage MJ; Barber BL; Harrison DJ; Jun S
Am J Manag Care; 2008 May; 14(5):317-22. PubMed ID: 18471035
[TBL] [Abstract][Full Text] [Related]
15. Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods.
Aly A; Onukwugha E; Woods C; Mullins CD; Kwok Y; Qian Y; Arellano J; Balakumaran A; Hussain A
BMC Med Res Methodol; 2015 Aug; 15():65. PubMed ID: 26286392
[TBL] [Abstract][Full Text] [Related]
16. Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases.
Carter JA; Ji X; Botteman MF
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):483-96. PubMed ID: 23862654
[TBL] [Abstract][Full Text] [Related]
17. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
[TBL] [Abstract][Full Text] [Related]
18. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
Duran I; Fink MG; Bahl A; Hoefeler H; Mahmood A; Lüftner D; Ghazal H; Wei R; Chung KC; Hechmati G; Green J; Atchison C
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 26865392
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
